ContentslistsavailableatScienceDirect
Colloids
and
Surfaces
B:
Biointerfaces
jou rn a l h om ep ag e :w w w . e l s e v i e r . c o m / l o c a t e / c o l s u r f b
Drug
delivery
system
based
on
cyclodextrin-naproxen
inclusion
complex
incorporated
in
electrospun
polycaprolactone
nanofibers
M.
Fatih
Canbolat
a,c,∗∗,
Asli
Celebioglu
a,b,
Tamer
Uyar
a,b,∗ aUNAM-NationalNanotechnologyResearchCenter,BilkentUniversity,Ankara06800,Turkey bInstituteofMaterialsScience&Nanotechnology,BilkentUniversity,Ankara06800,Turkey cSuleymanDemirelUniversity,EngineeringFaculty,TextileEngineering,Isparta32260,Turkeya
r
t
i
c
l
e
i
n
f
o
Articlehistory: Received4July2013
Receivedinrevisedform9November2013 Accepted11November2013
Availableonline19November2013 Keywords: Nanofibers Drug Cyclodextrin Inclusioncomplex Naproxen Release
a
b
s
t
r
a
c
t
Inthisstudy,we selectnaproxen(NAP) asareferencedrugand electrospunpoly(-caprolactone)
(PCL)nanofibersasafibrousmatrix forourdrug-deliverysystem.NAPwas complexedwith
beta-cyclodextrin(CD)toforminclusioncomplex(NAP-CD-IC)andthenNAP-CD-ICwasincorporated
intoPCLnanofibersviaelectrospinning.TheincorporationofNAPwithoutCD-ICintoelectrospunPCL
wasalsocarriedoutforacomparativestudy.OuraimistoanalyzethereleaseprofilesofNAPfrom
PCL/NAPandPCL/NAP-CD-ICnanofibersandweinvestigatetheeffectofCD-IContherelease
behav-iorofNAPfromthenanofibrousPCLmatrix.ThecharacterizationofNAP-CD-ICandthepresenceof
CD-ICinPCL/NAP-CD-ICnanofiberswerestudiedbyFTIR,XRD,TGA,NMRandSEM.TheSEMimaging
oftheelectrospunPCL/NAPandPCL/NAP-CD-ICnanofibersrevealthattheaveragefiberdiameterof
thesenanofibersisaround300nm,inaddition,theaggregatesofCD-ICinPCL/NAP-CD-ICnanofibersis
observed.ThereleasestudyofNAPinbuffersolutionelucidatethatthePCL/NAP-CD-ICnanofibershave
higherreleaseamountofNAPthanthePCL/NAPnanofibersduetothesolubilityenhancementofNAPby
CD-IC.
©2013ElsevierB.V.Allrightsreserved.
1. Introduction
Themainfunctionofdrugdeliverysystemsistotransport vari-ousdrugstothetargetsitesinthebodyinasecurewayandadjust thereleasemechanismsbycontrollingtheamountofdrugsand treatmenttime[1,2].Thereareseveralcarriersandformulations usedfordrugdeliverypurposessuchaspolymericmatrices,gels, cyclodextrins,liposomes,microspheres,foams,filmsandsome oth-ers[3–8].Indrugdelivery,itisexpectedfromacarriermaterialto haveatleastfollowingproperties;biocompatibility,non-toxicity, lackof immunogenicity, acceptablebiodegradationtime, repro-ducibility,andcontinuousactivationtillarrivaltothetarget[9,10]. Nanostructures and cyclodextrins (CD) present significant opportunities in drug delivery systems with their unique and promising characteristic features. Nanostructures improve the releasebehaviorandstabilityofthedrugsbymaintainingthedrug
∗ Correspondingauthorat:UNAM-NationalNanotechnologyResearchCenter, BilkentUniversity,Ankara06800,Turkey.Tel.:+903122903571;
fax:+903122664365.
∗∗ Correspondingauthorat:SuleymanDemirelUniversity,EngineeringFaculty, TextileEngineering,Isparta32260,Turkey.Tel.:+902462111188;
fax:+902462111180.
E-mailaddresses:fatihcanbolat@sdu.edu.tr(M.F.Canbolat), tamer@unam.bilkent.edu.tr(T.Uyar).
concentrationwithinatherapeuticwindowandovercomingthe biologicalbarriersforcellularuptake[11,12].Ontheotherhand, CDsinduceimprovementindrugreleaseprofilesandenhancement indrugsolubilizationandstabilizationbyforminginclusion com-plexes(ICs)withdrugs[13,14].However,thereisnostandardor idealstructureavailablefordrugdeliverypurposeandmany stud-iesarereportedondevelopingmuchbetterstructuresforthesite specificdrugtargeting[15–17].
Naproxen(NAP)isapoorlywatersoluble,non-steroidal anti-inflammatory drug (NSAIDs) that is used to relieve pain or inflammation [18,19]. Yet, enhanced solubilityachievements of naproxen by formingcyclodextrin inclusion complexes (CD-IC) were reported [20,21]. Apart from CD, the use of electrospun nanofibersasanincorporatingmatrixalsoenhancedtherelease behaviorofNAPincomparisonwithcastfilms[22].However,the main functionofelectrospunnanofibersin drugdelivery appli-cationscanbedefinedastheircontrolledandsustainedrelease behaviors[23,24].Indrugdeliveryfield,whilethere arestudies aboutincorporationofCDsintopolymericstructuressuchas hydro-gelsandfilms[25,26],averylimitednumberofreportsareavailable relatedtoincorporationofCD-ICofactiveagents suchasdrugs [27],antibacterials[28],essentialoils[29]andflavors/fragrances [30–33]intoelectrospunnanofibersfordeliveryandstabilization purposes.Forinstance,usingcyclodextrinasastabilizingand solu-bilizingagentandelectrospunnanofibermatsasacarriermatrix 0927-7765/$–seefrontmatter©2013ElsevierB.V.Allrightsreserved.
16 M.F.Canbolatetal./ColloidsandSurfacesB:Biointerfaces115(2014)15–21 forsustainedreleasemayopenupnewpathwaysfordrugdelivery
purposebasedonimprovedreleaseperformanceofthedrug. CDs(␣-,-,and ␥-types)are cyclic oligosaccharides which areenzymaticallyconvergedfromstarchthatcomprise glucopy-ranosideunitslinkedwith␣(1–4)bonds[34].CDsarehollowand truncatedconeshapedmoleculesthathavehydrophobiccavityand hydrophilicoutershellwhichenablethemtoconstitute noncova-lenthost–guestinclusioncomplexationwithvarietyofmolecules invariousforms[34,35].Ontheotherhand,electrospunnanofibers areotherpromisingnanostructuresindrugdeliveryapplications [36–38].Therearemanyreasonsfornanofiberstructurestobe pre-ferredandusedinbiomedicalapplicationareas,i.e.,smallfibersize, highporosity,interconnectedporousstructure,andcapabilityto embedvariousfunctionaladditivesintothem.
In this study, naproxen (NAP) and inclusion complex of naproxenwithbeta-cyclodextrin(NAP-CD-IC)wasincorporated intopolycaprolactone(PCL)electrospunnanofibersforour drug-deliverysystem.Wecompared therelease profilesofNAPfrom PCL/NAPand PCL/NAP-CD-ICnanofibersandwe examinedthe effectofinclusion complexationonthereleasebehavior ofNAP fromthenanofibrousPCLmatrix.Inthisregard,wefirsttestedthe effectofCDonthesolubilityofNAPbyforminginclusion complex-ation.NAPshowshighersolubilityinNAP-CD-ICwhencompared tofreeNAPwhichisconsistentwiththeliterature[39,40].Parallel tothisresult,improvedreleaseprofileofNAPfromPCL/NAP- CD-ICnanofibersisobserved,aswell.
2. Experimental 2.1. Materials
Naproxen (NAP) was commercially purchased from Abdi Ibrahim Pharmaceutical Company (Turkey). Polycaprolactone (PCL)(Mw:80,000,SigmaAldrich),N,N-dimethylformamide(DMF)
(Riedel,Pestanal),dicholoromethane (DCM)(Sigma,ExtraPure), and potassium dihydrogen phosphate (VWR, Chromanorm for HPLC)wereobtainedcommerciallyfromvarioussuppliers. Beta-cyclodextrin (CD) was obtained from Wacker Chemie AG (Germany)andthede-ionizedwaterwasobtainedfromthe Mil-liporeMilli-QUltrapure WaterSystem.Allmaterialswereused withoutanypurification.
2.2. ThepreparationofsolidˇCD-NAPinclusioncomplex (NAP-ˇCD-IC)
FortheNAP-CD-ICformation,1gofCDwasdissolvedin18ml waterand250mgNAPwasdispersedin2ml water,separately. Then,theNAPsolutionwasaddedintoCDsolutionslowly. Ulti-matesolutionwasstirredover-nightandaturbiddispersionwas obtained.Itwaskeptat−80◦Candfreeze-dried toobtain
NAP-CD-ICpowder.
2.3. Thepreparationofelectrospinningsolutions
TheNAP-CD-ICincludingPCLsolutionwasobtainedby dis-persingtheNAP-CD-ICpowderinclearandhomogenousPCL(15% (w/v),withrespecttosolvent)DMF/DCM(3:1,v/v)solution,atthe 20%(w/w)polymerconcentration.Forcomparison,thepurePCL (15%,w/v)andonlyNAPincluding(4%(w/w)withrespectto poly-merconcentration)PCL(15%,w/v)solutionswerealsopreparedin DMF/DCM(3/1,v/v)blendsystem.
2.4. Electrospinning
ThePCL,PCL/NAPandPCL/NAP-CD-ICsolutionswereplaced ina 3mlsyringe fittedwitha metallic needle of 0.6mm inner
diameter. The syringe was fixed horizontally on the syringe pump (model SP 101IZ, WPI, USA). The positive electrode of thehigh-voltagepowersupply (MatsusadaPrecision,AUSeries, Japan)wasclampedtothemetalneedle tip,and thecylindrical aluminum collectorwasgrounded.The parameters ofthe elec-trospinningwereadjustedas;feedrateofsolutions=1ml/h,the appliedvoltage=15kV,andthetip-to-collector distance=10cm. Electrospunnanofibersweredepositedonagroundedstationary cylindricalmetalcollectorcoveredwithapieceofaluminumfoil. TheelectrospinningapparatuswasenclosedinaPlexiglasbox,and electrospinningwascarried outat25◦C,20% relativehumidity. Thecollectednanofibersweredriedatroomtemperatureunder thefumehoodovernight.
2.5. Measurementsandcharacterization
TheexactmolarratiobetweenNAP:CDintheinclusion com-plexwasdeterminedbyusingprotonnuclearmagneticresonance (1HNMR,BrukerDPX-400)system.TheNAP-CD-ICpowderwas
dissolvedind6-DMSO(in20g/Lconcentration).Thespectrawere recordedat 400MHz and at16 total scan. A rheometer(Anton PaarPhysicaCR301)equippedwithacone/plateaccessory (spin-dletypeCP40-2)wasusedtomeasuretherheologicalbehaviorof PCL,PCL/NAPandPCL/NAP-CD-ICsolutionintherangeof0.1to 1001/sshearrate.Thescanningelectronmicroscope(SEM)(FEI Quanta200FEG)wasusedforthemorphologicalanalysisofthe electrospunnanofibers.Samplesweresputteredwith5nmAu/Pd priortoSEMimaging.Theaveragefiberdiameter(AFD)was deter-minedfromtheSEMimages,andaround100fiberswereanalyzed. The crystallinestructure determination of the NAP, CD, NAP-CD-ICpowderandPCL,PCL/NAPandPCL/NAP-CD-ICnanofibers wereinvestigated byusingX-raydiffraction(XRD) (PANalytical X’Pertpowderdiffractometer)havingCuK␣radiationinarangeof 2=5–30◦.Thethermalpropertiesofelectrospunnanofiberswere studiedbythermogravimetricanalysis(TGA)(TAQ500)andthe measurementswerecarriedout from25to500◦C at20◦C/min heatingrate,andN2wasusedasapurgegas.Theinfraredspectraof
thenanofiberswereobtainedbyusingaFouriertransforminfrared spectrometer(FTIR)(Bruker-VERTEX70).For measurement,the samplesweremixedwithpotassiumbromide(KBr)andpressed aspellets.Thescans(64scans)wererecordedbetween4000cm−1 and400cm−1ataresolutionof4cm−1.UV–vis-spectroscopy (Var-ianCary5000) wasused todeterminethesolubility difference betweenpureNAPandNAP-CD-IC.Forthispurpose,5×10−4M NAPpowderandNAP-CD-ICthatincludesthesameamountof NAPweredissolvedinwater.After24hstirring,thesolutionswere filteredandtheUVabsorbanceofsampleswasmeasuredinthe 250–370nmrange.
2.6. TheNAPreleaseprofilefromelectrospunPCLnanofibers TheHPLCsystem(Agilent1200Series)wasusedtoinvestigate thereleaseprofilesofPCL/NAP andPCL/NAP-CD-ICnanofibers. TheseparationofNAPwasperformedwithZorbaxEclipseXDB-C18 column(150mm×4.6mm,5mparticlesize)anditwasdetected at 230nm wavelength. Acetonitrile (100%) was used asmobile phaseataflowrateof1ml/minandtheinjectionvolumewaskept at10l.Forthetest,30mgweightedPCL/NAPandPCL/NAP- CD-ICnanofiberswereimmersedinto30mlbuffersolutionsandthey werekeptinthatbuffertodeterminethereleasedamountofNAP attheprogressingtimeintervals.Theexperimentswererepeated threetimesforbothcompositenanofibers.Thecalibrationcurve of NAP was prepared by using stock solutions in 7 different concentrations;20ppm, 10ppm, 5ppm, 2ppm, 1ppm, 0.5ppm and0.2ppm.ItshowedlinearityandacceptabilitywithR2≥0.99.
Fig.1.1HNMRspectrumofNAP-CD-ICdissolvedind6-DMSO.
Themeasurementresultswereadaptedtothiscalibrationcurve intermsofpeakareaundercurves.
3. Resultsanddiscussion
Naproxen(NAP)waschosenasareferencedruginthisstudy based on its well-known inclusion complex formation ability withbeta-cyclodextrin(CD)[19,41,42].Thereleasebehaviorof NAPafterdirectincorporationintoPCLnanofibers(PCL/NAP)and afterNAP-CD-ICformationandincorporationintoPCLnanofibers (PCL/NAP-CD-IC)wereexaminedinthepresentstudy.Themain objectiveofthisstudyistogetbetterreleaseprofileofNAPfrom PCL/NAP-CD-ICnanofibersduetohighersolubilityenhancement ofNAPbyCD-ICformation.
In the first step, NAP-CD-IC was formed by freeze-drying method.Themixingratiosof1:4(w/w)waschosenforNAP-CD to provide molar ratio as 1:1.2 for the proper inclusion com-plex formation. In further steps, several characterization tests were performed to prove theinclusion complex formation. To testthesolubilityofNAP byCD-ICformation,UV–visanalysis wasperformed.Then,releaseprofilesofNAPfromPCL/NAPand PCL/NAP-CD-ICnanofibrousmatsinbuffersolutionswere ana-lyzedbyHPLCmethod.
3.1. Inclusioncomplexcharacterization
1HNMRstudywasperformedtofigureoutthemolarratioof
NAP-CDandamountofNAPintheinclusioncomplex.Fig.1 indi-catesthe1HNMRspectrumoftheNAP-CD-ICpowder.Themolar
ratiowascalculatedbytakingtheintegralofNAPpeakatabout 1.4ppm[43]andCD’scharacteristicpeakatabout4.8ppm[44]in d6-DMSOsystem.Itwasfoundthat,NAP-CD-IChave1:1.2molar ratiowhentheintegralsofmentionedpeakswereproportionedto eachotherandthisratioisquitewellagreewithourinitialmixing ratio.
Then,weusedFTIRspectroscopytoobservethespectralchanges and therepresentative bands of thespectrafor the substances beforeandafterICformation.TheFTIRspectraofpureNAP,pure CDandNAP-CD-ICaredepictedinFig.2a.IntheFTIRspectrum ofNAP,distinctabsorptionbandat1029cm−1correspondstoC O stretching,at1228cm−1 correspondsto O stretching,and at 1395cm−1 correspondstoCH3 bending.Peaksat1685cm−1 and
1729cm−1correspondtoanti-symmetricalandsymmetricalC O stretchingvibrations[45,46].IncaseofCDspectra,characteristic peaksareappearedat1029cm−1,at1080cm−1and1157cm−1due toC Ostretch,at1638cm−1duetoH OHbending,at2927cm−1 duetoC Haliphaticstretch,andat3401cm−1duetoO H stretch-ing[45–47].TheFTIRspectrumofNAP-CD-ICshowsabandat about1730cm−1whichcomesfromNAPwithaslightshiftwhich isinanagreementwiththeliterature[41,42,46].Alsoitwasseen thattypicalpeaksoftheNAPweresuppressedintheNAP-CD-IC spectrawhichsuggestedthesuccessfulICformation.
Fig.2. FTIRspectraof(a)NAP,-CDandNAP-CD-IC,and(b)PCL,PCL/NAPand PCL/NAP-CD-ICnanofibers.
18 M.F.Canbolatetal./ColloidsandSurfacesB:Biointerfaces115(2014)15–21
Fig.3.XRDdiffractionpatternsof(a)NAP,-CDandNAP-CD-IC,and(b)PCL, PCL/NAPandPCL/NAP-CD-ICnanofibers.
TheXRDpatternsofthepureNAP,pureCDandNAP- CD-IC were recorded toinvestigate thepossible differences in the crystallinityofthestructures.AsitcanbeseenfromFig.3a,for theNAP-CD-IC,distinctdiffractionpeaksforthecrystallineNAP weredetectedintheXRDpatternsindicatingthatsomefreeNAP presentintheNAP-CD-ICpowder.Alsothecharacteristicpeaks ofchannel-typepackingstructureat2∼12◦,18◦,and19◦ofCD wereobservedfortheNAP-CD-ICwhichshowsthesuccessfulIC formationofNAPwithCD[48].
TGAthermogramsofpureNAP,pureCDandNAP-CD-ICare shown inFig. 4a. TGAthermogramsshow weightlosses below 100◦CforbothCDandNAP-CD-ICduetowaterlossandmain degradation wasobserved for NAP at 268◦C and at 350◦C for CD.Thewaterlosswasabout11%forCDwhileitwasaround 8%for NAP-CD-IC.The 3%difference mightbe attributableto theexistenceofNAP insteadofwater intheCD cavity.Other thantheinitialweightloss,therearetwoweightlossesseenfor NAP-CD-IC.Firstoneisbetween150◦C and250◦Candsecond oneisbetween300◦Cand350◦CwhichcorrespondstofreeNAP and IC weight losses that merged with theCD decomposition, respectively.Therelativelessdecomposedamountofuncomplexed free NAP than the initial amount and the higher temperature shift in the NAP–CD part prove the successful formation of NAP-CD-IC.
TheUV–visspectroscopymeasurementsofNAPandNAP- CD-ICsolutionsweredisplayedinFig.5.Asitcanbeseenfromthe spectra,theabsorptionintensityofNAP-CD-ICsolutionishigher thanNAP powder for thesameamount ofNAP (5×10−4M).It ismainlybecause,theinclusioncomplexationofNAPwithCD enhancethesolubilityofinsolubledrug,NAP,in watermedium andleadstohigherintensityoccurrenceinUV–vis-spectra.Thus, theinclusioncomplexationandthesolubilityenhancementarealso provedbytheUV–vismeasurements.
Fig.4.TGAthermogramsof(a)NAP,-CDandNAP-CD-IC,and(b)PCL,PCL/NAP andPCL/NAP-CD-ICnanofibers.
3.2. Characterizationofelectrospunnanofibers
Following the characterization studies of NAP-CD-IC, PCL polymer matrix was chosen for the production of electrospun nanofibers.SincePCLiswaterinsolubleandbiodegradable poly-mer[49,50],itisthoughtthattheuseofPCLnanofibersasadrug deliverysystemmightexhibitconvenientreleaseprofileforNAP. FollowingconcentrationadjustmentsofthePCL/NAPand PCL/NAP-CD-ICblends,electrospinningandcharacterizationstudieswere performed.
Weinvestigatedthemorphologyofelectrospunnanofibersof purePCL,PCL/NAPandPCL/NAP-CD-ICbySEMimaging.The rep-resentativeimagesofSEMmicrographsweregiveninFig.6and fiberdiameterdistributiondataweresummarizedinTable1. Uni-form,beadfreenanofiberswithdiametervariationwereobtained fromallthreePCLbasednanofibroussamples.Itis clearlyseen intheFig.6cthatthereareICcrystalaggregatesaccumulatedin
Fig.5.SolubilityanalysisofNAPbyUV–visspectroscopy;solubilityofpureNAPand solubilityofNAPfromNAP-CD-IC.
Table1
Polymersolutionparametersandaveragefiberdiametervaluesofelectrospunnanofibers(thefibersizeisreportedastheaverage±standarddeviation;foreachcase100 fiberswereanalyzed).
Solvents Concentrations Viscosity(Pas) Averagefiberdiameter(nm)
PCL DMF/DCM(3:1,v/v) 15%(w/v) 0.465 336±100
PCL/NAP DMF/DCM(3:1,v/v) 15%(w/v)/4%(w/w) 0.675 361±152
PCL/NAP-CD-IC DMF/DCM(3:1,v/v) 15%(w/v)/20%(w/w) 0.745 389±167
thefibermatrixwhichprovesthesuccessfulincorporationof
NAP-CD-ICintoelectrospunPCLnanofibers.Itwasfoundoutthatfiber
diameterdistributions have good correlationwiththeviscosity
measurementresultsascanbeseeninTable1.Theincorporation
ofNAPandNAP-CD-ICintoPCLmatrixcausedviscosityincrease inthepolymersolutionswhichfinallytriggeredtheformationof nanofiberswithlargerdiameters.
WeperformedFTIRstudiesfornanofibersofpurePCL,PCL/NAP andPCL/NAP-CD-ICsamples(Fig.2b).TypicalpeaksforthePCLare observedat2949cm−1and2865cm−1duetoCH2stretching
vibra-tions,at1731cm−1duetoC Ostretchingvibrations,at1471cm−1, 1397cm−1,and 1365cm−1 due toCH2 bendingvibrations.Also
C OandC Cstretchingvibrationsat1293cm−1,C O C stretch-ingvibrationsat1240cm−1,1169cm−1,1108cm−1,and1048cm−1 wedetected[51–53].InFTIRspectraofPCL/NAPnanofibers,the characteristicpeaksofPCLmostlyexistwhilenoneofthe character-isticpeaksofNAPwasobservedwhichismostprobablyduetothe dominanteffectofthePCLpeaksandtherelativelylow concentra-tionofNAPinthepolymermatrix(∼4%,w/w).Forinstance,almost allthepeaksinthefingerprintregionarequitewellfittedwith PCLcharacteristicpeaks.However,thereisagoodindicationabout theexistenceofNAPduetosomeshiftedpeaksat2869cm−1and 2952cm−1whiletheyarelocatedat2865cm−1and2949cm−1in thePCLspectra.TheFTIRspectrumofPCL/NAP-CD-ICnanofibers hasverysimilarcharacteristicfeatureswithPCL/NAPnanofibers. Again,PCLpeakswereoversaturatedinthespectrawhileCD-IC peaksweresuppressed,evenoneofthemostdistinctpeakofCD at1029cm−1isnotvisible.AlthoughtheFTIRspectradidnotdepict
Fig.6. SEMmicrographsof(a)PCL,(b)PCL/NAPand(c)PCL/NAP-CD-ICnanofibers.
anyinteractionbetweenPCLand NAP-CD-ICin terms ofpeak shifts,wecannotrule-outsuchcase.Itisduetothefactthatthe signalfromtheFTIRspectraoriginatesfromtwospecies,namely, interactionandnon-interactionofPCLwithNAP-CD-IC.Alsowe haveonly4%ofNAPinPCLandhencethesignalispredominantly comingfromPCL.
X-raydiffractionpatternsofpurePCL,PCL/NAPand PCL/NAP-CD-ICnanofibrousmatsaregiveninFig.3b.NAPandNAP-CD-IC arecrystallinematerials,however,theXRDpatternsofPCL/NAP andPCL/NAP-CD-ICnanofibrousmatsrevealedthat both NAP-CD-ICandNAPtransformedintoamorphousphasefollowingthe incorporationintothePCLnanofibrousmatrix.
In TGA thermograms,main degradation of NAP in PCL/NAP nanofiberswasfoundoutbetween200–250◦Cwhilefor PCL/NAP-CD-ICnanofibers, it wasfound outbetween 300–375◦C from theTGAanalysis.TheTGAthermograminFig.4brevealsthatPCL nanofibersshowmaindegradationatabout420◦C.BylookingTGA thermograms,itispossibletoclaimtheexistenceofNAPmolecules andNAP-CD-ICinthePCL/NAP-CD-ICnanofibers.Inbothcases, forPCL/NAP andPCL/NAP-CD-ICnanofibers,two weightlosses wereseenafter100◦Cwhichareindependentfromwaterlosses.
We studied the release profiles of NAP from PCL/NAP and PCL/NAP-CD-ICnanofibersinbuffersolutionforabout20htime period by HPLC. The amount of PCL/NAP and PCL/NAP-CD-IC nanofibersusedforthereleasestudywasadjustedaccordinglyin ordertohavethesameamountofNAPinthesesamples.Forboth samples,afterslightburstingofthedrug,slowreleasebehavior wasobservedfor12hperiod.Then,NAPshowedsustainedrelease profilesduetothebalancedconditionssuchashavingsame diffu-sionresistancefordifferenttimeintervals[54].Thereleaseprofiles revealedthatPCL/NAP-CD-ICnanofibroussystemhasmorethan twotimeshigherreleaseratethanPCL/NAPnanofibroussystem whichisverypromisingresultforthedrugdeliverypurpose(Fig.7). ItalsorevealedthattheformationofNAP-CD-IChelpedNAPto releasefromnanofibrousmatmucheasierwhichisquitevitalin drugdeliveryapplications.Asitwasprovenbyoursolubilitytest, CD-ICformationhelpsNAPtodissolveinwatermuchbetterwhich showsitseffectonthereleasebehaviorofNAPafterincorporated intonanofibrousmat.Theeasyandhigherreleaseofdrugis impor-tantfor somespecifictargetsindrugdelivery.It iswell-known
Fig.7.ReleaseprofileofNAPfromPCL/NAPandPCL/NAP-CD-ICnanofibrousmats byHPLCwithstandarddeviations(eachanalysisrepeated3times,n=3).
20 M.F.Canbolatetal./ColloidsandSurfacesB:Biointerfaces115(2014)15–21 phenomenathatnanofiberscanenhancethereleasebehaviorof
drugswiththeirhighsurfaceareatovolumeratio[55,56].Inthis study,thepositiveeffectofinclusioncomplexformationonthe releaseprofilesofNAPinadditiontonanofiberincorporationhas beendemonstratedandthismaybeapromisingresultfordesigning noveldrugdeliverysystems.
4. Conclusions
Themainideabehindthisstudywastocomparetheefficiencies oftwodifferentdeliverysystemsfortheNAP;direct incorpora-tionofNAPandNAPincludedcomplexincorporationfollowingIC formationwithCDintoelectrospunPCLnanofibers.Initially,the formationofNAP-CD-ICwasstudiedandthentheincorporation ofNAPandNAP-CD-ICintoPCLnanofiberswasperformedvia electrospinning.ThereleaseperformanceoftheNAPwasincreased morethantwotimesincaseofPCL/NAP-CD-ICnanofiberswhen comparedwithPCL/NAP nanofibers.Thus, it is understoodthat incorporationofNAP-CD-ICinapolymericnanofibroussystem stillpreservetheimprovedsolubilityeffectofCD-IContherelease rateofNAPandprovidesastableenvironmentforit.
Acknowledgment
StatePlanningOrganization(DPT)ofTurkeyisacknowledged for the support of UNAM-National Nanotechnology Research Center, BilkentUniversity. Dr. T. Uyar acknowledges TUBITAK-The Scientific and Technological Research Council of Turkey (project#111M459)andEUFP7-PEOPLE-2009RGMarieCurie-IRG (NANOWEB,PIRG06-GA-2009-256428)andTheTurkishAcademy ofSciences-OutstandingYoungScientistsAwardProgram (TUBA-GEBIP)for funding the research. A. Celebioglu acknowledges TUBITAK-BIDEBforthenationalPh.D.studyscholarship.
References
[1]T.M.Allen,P.R.Cullis,Drugdeliverysystems:enteringthemainstream,Science 303(2004)1818–1822.
[2]J.L. Frandsen, H. Ghandehari, Recombinant protein-based polymers for advanceddrugdelivery,Chem.Soc.Rev.41(2012)2696–2706.
[3]J.H.Jung,J.H.Lee,J.R.Silverman,G.John,Coordinationpolymergelswith impor-tantenvironmentalandbiologicalapplications,Chem.Soc.Rev.42(2013) 924–936.
[4]Y.Zhang,J.Zhang,T.Jiang,S.Wang,Inclusionofthepoorlywater-soluble drugsimvastatininmesocellularfoamnanoparticles:drugloadingandrelease properties,Int.J.Pharm.410(2011)118–124.
[5]R.Machin,J.R.Isasi,I.Vélaz,-Cyclodextrinhydrogelsaspotentialdrugdelivery systems,Carbohydr.Polym.87(2012)2024–2030.
[6]J.Kowapradit,A.Apirakaramwong,T.Ngawhirunpat,T.Rojanarata,W. Sajom-sang, P.Opanasopit, MethylatedN-(4-N,N-dimethylaminobenzyl)chitosan coatedliposomesfororalproteindrugdelivery,Eur.J.Pharm.Sci.47(2012) 359–366.
[7]E.D‘Aurizio,P.Sozio,L.S.Cerasa,M.Vacca,L.Brunetti,G.Orlando,A.Chiavaroli, R.J.Kok,W.E.Hennink,A.D.Stefano,Biodegradablemicrospheresloadedwith ananti-parkinsonprodrug:aninvivopharmacokineticstudy,Mol.Pharm.8 (2011)2408–2415.
[8]J.B.Wolinsky,Y.L.Colson,M.W.Grinstaff,Localdrugdeliverystrategiesfor can-certreatment:gels,nanoparticles,polymericfilms,rods,andwafers,J.Control. Release159(2012)14–26.
[9]S.D.Koker,R.Hoogenboom,B.G.D.Geest,Polymericmultilayercapsulesfor drugdelivery,Chem.Soc.Rev.41(2012)2867–2884.
[10]J.H.Kang,D.H.Oh,Y.-K.Oh,C.S.Yong,H.-G.Choi,Effectsofsolidcarriersonthe crystallineproperties,dissolutionandbioavailabilityofflurbiprofeninsolid self-nanoemulsifyingdrugdeliverysystem(solidSNEDDS),Eur.J.Pharm. Bio-pharm.80(2012)289–297.
[11]J.M.Rabanel,V.Aoun,I.Elkin,M.Mokhtar,P.Hildgen,Drug-loaded nanocarri-ers:passivetargetingandcrossingofbiologicalbarriers,Curr.Med.Chem.19 (2012)3070–3102.
[12]L.H.Reddy,J.L.Arias,J.Nicolas,P.Couvreur,Magneticnanoparticles:design characterizationtoxicitybiocompatibilitypharmaceuticalbiomedical applica-tions,Chem.Rev.112(2012)5818–5878.
[13]T.Loftsson,M.E.Brewster,Cyclodextrinsasfunctionalexcipients:methodsto enhancecomplexationefficiency,J.Pharm.Sci.101(2012)3019–3032.
[14]F.V.d.Manakker,T.Vermonden,C.F.V.Nostrum,W.E.Hennink, Cyclodextrin-based polymeric materials: synthesis, properties, and pharmaceutical/ biomedicalapplications,Biomacromolecules10(2009)3157–3175. [15]W.Gu,C.Wu,J.Chen,Y.Xiao,Nanotechnologyinthetargeteddrugdeliveryfor
bonediseasesandboneregeneration,Int.J.Nanomed.8(2013)2305–2317. [16]R. Cheng,F. Meng,C.Deng, H.-A.Klok,Z.Zhong,Dual andmulti-stimuli
responsivepolymericnanoparticlesforprogrammedsite-specificdrug deliv-ery,Biomaterials34(2013)3647–3657.
[17]M.A.Petersen,M.A.Hillmyer,E.Kokkoli,Bioresorbablepolymersomesfor tar-geteddeliveryofcisplatin,Bioconjug.Chem.24(2013)533–543.
[18]N.Sadlej-Sosnowska,L.Kozerski,E.Bednarek,J.Sitkowski,Fluorometricand NMRstudiesofthenaproxen-cyclodextrininclusioncomplexesinaqueous solutions,J.Incl.Phenom.Macrocycl.Chem.37(2000)383–394.
[19]A.Banik,P.Gogoi,M.D.Saikia,Interactionofnaproxenwith-cyclodextrinand itsderivatives/polymer:experimentalandmolecularmodelingstudies,J.Incl. Phenom.Macrocycl.Chem.72(2012)449–458.
[20]M.Cirri,F.Maestrelli,G.Corti,S.Furlanetto,P.Mura,Simultaneouseffectof cyclodextrincomplexation,pH,andhydrophilicpolymersonnaproxen solubi-lization,J.Pharm.Biomed.Anal.4(2)(2006)126–131.
[21]H.L.Ramírez,R.Cao,A.Fragoso,J.J.Torres-Labandeira,A.Dominguez,E.H. Schacht, M.Ba ˜nos, R. Villalonga, Improvedanti-inflammatory properties fornaproxenwithcyclodextrin-graftedpolysaccharides,Macromol.Biosci.6 (2006)555–561.
[22]S.Tungprapa,I.Jangchud,P.Supaphol,Releasecharacteristicsoffourmodel drugsfromdrug-loadedelectrospuncelluloseacetatefibermats,Polymer48 (2007)5030–5041.
[23]E.-R.Kenawy,F.I.Abdel-Hay,M.H.El-Newehy,G.E.Wnek,Processingof poly-mernanofibersthroughelectrospinningasdrugdeliverysystems,Mater.Chem. Phys.113(2009)296–302.
[24]T.J.Sill,H.A.v.Recum,Electrospinningapplicationsindrugdeliveryandtissue engineering,Biomaterials29(2008)1989–2006.
[25]M.J.Kutyla,L.K.Lambert,N.M.Davies,R.P.McGeary,P.N.Shaw,B.P.Ross, Cyclodextrin-crosslinkedpoly(acrylicacid):synthesis,physicochemical char-acterizationandcontrolledreleaseofdiflunisalandfluconazolefromhydrogels, Int.J.Pharm.444(2013)175–184.
[26]M.Jug,F.Maestrelli,P.Mura,Nativeandpolymeric-cyclodextrinsin per-formanceimprovementofchitosanfilmsaimedforbuccaldeliveryofpoorly solubledrugs,J.Incl.Phenom.Macrocycl.Chem.74(2012)87–97.
[27]T. Vigh, T. Horváthová, A. Balogh, P.L. Sóti, G. Drávavölgyi, Z.K. Nagy, G. Marosi,Polymer-freeand polyvinylpyrrolidone-basedelectrospunsolid dosageformsfordrugdissolutionenhancement,Eur.J.Pharm.Sci.49(2013) 595–602.
[28]F.Kayaci,O.C.O.Umu,T.Tekinay,T.Uyar,Antibacterialelectrospun polylac-ticacid(PLA)nanofibrouswebsincorporatingtriclosan/cyclodextrininclusion complexes,J.Agric.FoodChem.61(2013)3901–3908.
[29]F.Kayaci,Y.Ertas,T.Uyar,Enhancedthermalstabilityofeugenolbycyclodextrin inclusioncomplexencapsulatedinelectrospunpolymericnanofibers,J.Agric. FoodChem.61(2013)8156–8165.
[30]F.Kayaci,T.Uyar,Encapsulationofvanillin/cyclodextrininclusioncomplexin electrospunpolyvinylalcohol(PVA)nanowebs:prolongedshelf-lifeandhigh temperaturestabilityofvanillin,FoodChem.133(2012)641–649.
[31]T.Uyar,Y.Nur,J.Hacaloglu,F.Besenbacher,Electrospinningoffunctional poly(methyl methacrylate) (PMMA) nanofibers containing cyclodextrin-mentholinclusioncomplexes,Nanotechnology20(2009)125703.
[32]T.Uyar,J.Hacaloglu,F.Besenbacher,Electrospunpolyethyleneoxide(PEO) nanofiberscontainingcyclodextrininclusioncomplex,J.Nanosci.Nanotechnol. 5(2011)3949–3958.
[33]T.Uyar,J.Hacaloglu,F.Besenbacher,Electrospunpolystyrenefiberscontaining hightemperaturestablevolatilefragrance/flavorfacilitatedbycyclodextrin inclusioncomplexes,React.Funct.Polym.3(2009)145–150.
[34]J.Szejtli,Introductionandgeneraloverviewofcyclodextrinchemistry,Chem. Rev.98(1998)1743–1754.
[35]E.D.Valle,Cyclodextrinsandtheirusesareview,ProcessBiochem.39(2004) 1033–1046.
[36]S.T. Yohe,V.L.M.Herrera,Y.L.Colson,M.W.Grinstaff, 3D superhydropho-bicelectrospunmeshesasreinforcementmaterialsforsustainedlocaldrug delivery against colorectal cancer cells, J. Control. Release 162 (2012) 92–101.
[37]X. Li, M.A. Kanjwal, L. Lin, I.S. Chronakis, Electrospun polyvinyl-alcohol nanofibersasoralfast-dissolvingdeliverysystemofcaffeineandriboflavin, ColloidsSurf.B103(2013)182–188.
[38]R.Murugan,S.Ramakrishna,Nano-featuredscaffoldsfortissueengineering:a reviewofspinningmethodologies,TissueEng.12(2006)435–447.
[39]T. Miletic, K. Kyriakos, A. Graovac, S. Ibric, Spray-dried voriconazole– cyclodextrincomplexes:solubility,dissolutionrateandchemicalstability, Car-bohydr.Polym.98(2013)122–131.
[40]H.S.Mahajan,M.H.Pingale,K.M.Agrawal,Solubilityanddissolution enhance-ment ofsaquinavirmesylatebyinclusioncomplexationtechnique,J.Incl. Phenom.Macrocycl.Chem.76(2013)467–472.
[41]J.Blanco,J.L.Vila-Jato,F.Otero,S.Anguiano,Influenceofmethodofpreparation oninclusioncomplexesofnaproxenwithdifferentcyclodextrins,DrugDev.Ind. Pharm.17(1991)943–957.
[42]S.Junco,T.Casimiro,N.Ribeiro,M.N.D.Ponte,H.C.Marques,Acomparative study ofnaproxen–betacyclodextrincomplexespreparedbyconventional methodsandusingsupercriticalcarbondioxide,J.Incl.Phenom.Macrocycl. Chem.44(2002)117–121.
[43]E.Marco-Urrea,M.Pérez-Trujillo,P.Blánquez,T.Vicent,G.Caminal, Biodegra-dationoftheanalgesicnaproxenbytrametesversicolorandidentificationof intermediatesusingHPLC-DAD-MSandNMR,Bioresour.Technol.101(2010) 2159–2166.
[44]S.Divakar,M.Maheswaran,Structuralstudiesoninclusioncompoundsof -cyclodextrinwithsomesubstitutedphenols,J.Incl.Phenom.Macrocycl.Chem. 27(1997)113–126.
[45]H.E.Grandelli,B.Stickle,A.Whittington,E.Kiran,Inclusioncomplexformation of-cyclodextrinandnaproxen:astudyonexothermiccomplexformationby differentialscanningcalorimetry,J.Incl.Phenom.Macrocycl.Chem.77(2013) 269–277.
[46]M.Valero,B.I.Perez-Revuelta,L.J.Rodriguez,EffectofPVPK-25ontheformation ofthenaproxen:-cyclodextrincomplex,Int.J.Pharm.253(2003)97–110. [47]L.-F.Chen,Q.Shen,J.-P.Shen,D.-T.Shi,T.Chen,H.-R.Yu,Studiesandcomparison
oftheliquidadsorptionandsurfacepropertiesof␣-,-,and␥-cyclodextrins byFTIRandcapillaryrisemethod,ColloidsSurf.A411(2012)69–73. [48]A.Harada,M.Okada,J.Li,M.Kamachi,Preparationandcharacterizationof
inclu-sioncomplexesofpoly(propyleneglycol)withcyclodextrins,Macromolecules 28(1995)8406–8411.
[49]K.Tapan,T.K.Dash,V.B.Konkimalla,Poly--caprolactonebasedformulations fordrugdeliveryandtissueengineering:areview,J.Control.Release158(2012) 15–33.
[50]C.Wu,T.F.Jim,Z.Gan,Y.Zhao,S.Wang,Aheterogeneouscatalytickineticsfor enzymaticbiodegradationofpoly(-caprolactone)nanoparticlesinaqueous solution,Polymer41(2000)3593–3597.
[51]A.Elzubair,C.N.Elias,J.C.M.Suarez,H.P.Lopes,M.V.B.Vieira,Thephysical char-acterizationofathermoplasticpolymerforendodonticobturation,J.Dent.34 (2006)784–789.
[52]S.A.Catledge,W.C.Clem,N.Shrikishen,S.Chowdhury,A.V.Stanishevsky,M. Koopman,Y.K.Vohra,Anelectrospuntriphasicnanofibrousscaffoldforbone tissueengineering,Biomed.Mater.2(2007)142–150.
[53]L.Ghasemi-Mobarakeh,M.P.Prabhakaran,M.Morshed,M.H.Nasr-Esfahani, S.Ramakrishna,Bio-functionalizedPCLnanofibrousscaffoldsfornervetissue engineering,Mater.Sci.Eng.C30(2010)1129–1136.
[54]X.Sheng,L.Fan,C.He,K.Zhang,X.Mo,H.Wang,VitaminE-loadedsilkfibroin nanofibrousmatsfabricatedbygreenprocessforskincareapplication,Int.J. Biol.Macromol.56(2013)49–56.
[55]X.-Z.Sun,G.R.Williams,X.-X.Hou,L.-M.Zhu,Electrospuncurcumin-loaded fiberswithpotentialbiomedicalapplications,Carbohydr.Polym.94(2013) 147–153.
[56]D.W.Chen,Y.-H.Hsu,J.-Y.Liao,S.-J.Liu,J.-K.Chen,S.W.-N.Ueng, Sustain-ablereleaseofvancomycin,gentamicinandlidocainefromnovelelectrospun sandwich-structuredPLGA/collagennanofibrousmembranes,Int.J.Pharm.430 (2012).